10 assets in BRCA1-Related Cancer Predisposition

Therapeutic assets addressing BRCA1-Related Cancer Predisposition, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Olaparib BRCA1-Related Cancer Predisposition	M.D. Anderson Cancer Center	P2	BB (69)
Niraparib BRCA1-Related Cancer Predisposition	Qian Qin	P3	B (63)
Abiraterone BRCA1-Related Cancer Predisposition	Qian Qin	P2	CCC (53)
Cediranib BRCA1-Related Cancer Predisposition	M.D. Anderson Cancer Center	P2	CCC (53)
Ceralasertib BRCA1-Related Cancer Predisposition	M.D. Anderson Cancer Center	P2	CCC (53)
Docetaxel BRCA1-Related Cancer Predisposition	Qian Qin	P2	CCC (53)
Dostarlimab BRCA1-Related Cancer Predisposition	Dana-Farber Cancer Institute	P2	CCC (53)
Pembrolizumab BRCA1-Related Cancer Predisposition	Rutgers, The State University of New Jersey	P2	CCC (53)
Prednisone BRCA1-Related Cancer Predisposition	Qian Qin	P2	CCC (53)
Talazoparib BRCA1-Related Cancer Predisposition	Pfizer	P2	CCC (53)